Atypical pituitary adenomas: incidence, clinical characteristics, and implications
- PMID: 20868211
- DOI: 10.3171/2010.8.JNS10290
Atypical pituitary adenomas: incidence, clinical characteristics, and implications
Abstract
Object: The 2004 WHO classification of pituitary adenomas now includes an "atypical" variant, defined as follows: MIB-1 proliferative index greater than 3%, excessive p53 immunoreactivity, and increased mitotic activity. The authors review the incidence of this atypical histopathological subtype and its correlation with tumor subtype, invasion, and surgical features.
Methods: The records of 121 consecutive patients who underwent transsphenoidal surgery for pituitary adenomas during an 18-month period were retrospectively reviewed for evidence of atypical adenomas.
Results: Eighteen adenomas (15%) met the criteria for atypical lesions; 17 (94%) of the 18 were macroadenomas. On imaging, 15 (83%) demonstrated imaging evidence of surrounding invasion, compared with 45% of typical adenomas (p = 0.004). Atypical tumors occurred in 12 female (67%) and 6 male (33%) patients. Patient age ranged from 16 to 70 years (mean 48 years). Nine patients (50%) had hormonally active tumors, and 9 had nonfunctional lesions. Four (22%) of the 18 patients presented to us with recurrent tumors. Immunohistochemical analysis demonstrated the following tumor subtypes: GH-secreting adenoma with plurihormonal staining (5 patients [28%]); null-cell adenoma (5 patients [28%]); silent ACTH tumor (3 patients [17%]), ACTH-staining tumor with Cushing's disease (2 patients [11%]), prolactinoma (2 patients [11%]), and silent FSH-staining tumor (1 patient [6%]). The MIB-1 labeling index ranged from 3% to 20% (mean 7%).
Conclusions: Atypical tumors were identified in 15% of resected pituitary adenomas, and they tended to be aggressive, invasive macroadenomas. More longitudinal follow-up is required to determine whether surgical outcomes, potential for recurrence, or metastasis of atypical adenomas vary significantly from their typical counterparts.
Similar articles
-
Atypical pituitary adenoma: a clinicopathologic case series.J Neurosurg. 2018 Apr;128(4):1058-1065. doi: 10.3171/2016.12.JNS162126. Epub 2017 Jun 9. J Neurosurg. 2018. PMID: 28598278
-
Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.Neurosurg Rev. 2017 Jan;40(1):105-114. doi: 10.1007/s10143-016-0740-9. Epub 2016 May 23. Neurosurg Rev. 2017. PMID: 27215912
-
Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.Neuroendocrinology. 2015;101(2):143-50. doi: 10.1159/000375448. Epub 2015 Jan 29. Neuroendocrinology. 2015. PMID: 25633744
-
Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.Neurol Res. 2010 Dec;32(10):1060-71. doi: 10.1179/016164110X12670144737855. Epub 2010 May 18. Neurol Res. 2010. PMID: 20483025 Review.
-
Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.Eur J Endocrinol. 2007 Feb;156(2):203-16. doi: 10.1530/eje.1.02326. Eur J Endocrinol. 2007. PMID: 17287410 Review.
Cited by
-
The biological behavior and clinical outcome of pituitary adenoma are affected by the microenvironment.CNS Neurosci Ther. 2024 May;30(5):e14729. doi: 10.1111/cns.14729. CNS Neurosci Ther. 2024. PMID: 38738958 Free PMC article. Review.
-
Multidisciplinary Team Care in Pituitary Tumours.Cancers (Basel). 2024 Feb 27;16(5):950. doi: 10.3390/cancers16050950. Cancers (Basel). 2024. PMID: 38473312 Free PMC article. Review.
-
Plurihormonal Pituitary Neuroendocrine Tumors: Clinical Relevance of Immunohistochemical Analysis.Diagnostics (Basel). 2024 Jan 11;14(2):170. doi: 10.3390/diagnostics14020170. Diagnostics (Basel). 2024. PMID: 38248047 Free PMC article.
-
Pituitary carcinoma: reclassification and implications in the NET schema.Endocr Oncol. 2022 Mar 30;2(1):R14-R23. doi: 10.1530/EO-22-0041. eCollection 2022 Jan. Endocr Oncol. 2022. PMID: 37435449 Free PMC article. Review.
-
The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary.Cancers (Basel). 2023 May 11;15(10):2710. doi: 10.3390/cancers15102710. Cancers (Basel). 2023. PMID: 37345047 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous